Simpson Thacher represented the initial purchasers, led by joint bookrunning managers J.P. Morgan Securities LLC, Credit Suisse Securities (USA) LLC, Goldman, Sachs & Co., UBS Securities LLC, Deutsche Bank Securities Inc., Morgan Stanley & Co. LLC and Barclays Capital Inc. in the sale of $1.125 billion aggregate principal amount of 6.375% Senior Notes due 2023 by Jaguar Holding Company II, an indirect parent of Pharmaceutical Product Development, LLC (“PPD”), and PPD (collectively, the “Issuers”). The Issuers used the proceeds from the offering, together with borrowings under the Issuers’ new senior secured credit facilities and cash on hand, to refinance existing debt and to pay a dividend to their stockholders.
PPD is a leading global contract research organization providing clinical development and laboratory services to companies in the biopharmaceutical industries, in addition to academic, non-profit and government organizations.
The Simpson Thacher team included Art Robinson, Ryan Bekkerus, Sung Bum Cho and Clark Warthen (Capital Markets); Jon Cantor and Jodi Sackel (Tax); Paul Koppel and Alexander Cahn (Executive Compensation and Employee Benefits); Genevieve Dorment (IP); Mike Isby (Environmental); and Andrew Pagliughi (Blue Sky). Summer Associate Sarah Pelham also provided valuable assistance.
Source: www.stblaw.com
